Eurofins, FR0014000MR3

Eurofins completes two portfolio deals: Eurofins stock sits 3.64 percent below its 52-week high

Published on 10/07/2026 at 10:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half 2026 earnings per share grew 29 percent, margin rose 130 basis points. Eurofins stock costs EUR 76.34 versus EUR 75.81, plus 0.70 percent, on October 7, 2026.

Geometrisches Bauhaus-Poster mit Formen und Schriftzügen LAB und TESTING in Primärfarben
Bauhaus-Poster mit Schriftzügen LAB und TESTING illustriert die Branche von Eurofins Scientific SE, ISIN FR0014000MR3, Illustration mit AI erstellt.

Eurofins Scientific SE (ISIN FR0014000MR3) was trading at EUR 76.34 at Lang & Schwarz on October 7, 2026 at 10:19 a.m. CEST, 3.64 percent below its 52-week high of EUR 79.22. On October 2, Eurofins reported the October 1 completion of its USD 400 million Element acquisition, while a second Eurofins release detailed the EUR 575 million sale of MET Labs to UL Solutions.

Two deals reshape the portfolio

The Element business adds 27 laboratories and facilities across North America, with approximately 750 employees. Eurofins expects the acquired operations to generate more than USD 150 million in annual revenue in 2026, with profitability similar to the group average.

The divestment removes an electrical and electronic testing business with approximately 1,300 staff. Eurofins said the proceeds will support debt reduction, laboratory investment, digital solutions, robotics, artificial intelligence, share buybacks and strategic acquisitions.

Margin progress meets portfolio change

For investors, the important comparison is between portfolio scale and operating improvement. The Eurofins investor page says first-half 2026 adjusted EBITDA margin expanded by 130 basis points and earnings per share grew 29 percent year on year, providing a quantified backdrop for the transactions.

The same investor page lists a 24 percent adjusted EBITDA margin objective for fiscal 2027 and a long-term average growth objective of 6.50 percent per year. These objectives put the newly acquired revenue contribution beside a defined profitability path rather than treating the acquisition as a standalone expansion move.

Capital returns are also visible in the latest transaction report. Morningstar reported that Eurofins repurchased 565,000 shares from September 28 through October 2 at a weighted average price of EUR 75.1865.

Stock stays below its yearly high

Eurofins stock was trading at EUR 76.34 at Lang & Schwarz on October 7, 2026 at 10:19 a.m. CEST, up EUR 0.53 or 0.70 percent versus the EUR 75.81 prior close of October 6, 2026. The finance quote showed a 52-week range of EUR 54.86 to EUR 79.22 and market capitalization of EUR 13.2 billion as of October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of Eurofins stock.

Eurofins stock facts

  • Company: Eurofins Scientific SE
  • ISIN: FR0014000MR3
  • Ticker: ERF
  • Primary exchange: Euronext Paris
  • Price Lang & Schwarz (as of October 7, 2026, 10:19 a.m. CEST): EUR 76.34
  • Change versus prior close: plus 0.70 percent
  • Prior close Lang & Schwarz (October 6, 2026): EUR 75.81
  • Market capitalization: EUR 13.2 billion (as of October 7, 2026)
  • 52-week range: EUR 54.86-EUR 79.22 (as of October 7, 2026)
  • Sector / Industry: Healthcare / Medical Diagnostics and Research

More news and analyses on Eurofins stock

Disclaimer...

en | FR0014000MR3 | EUROFINS | boerse | 70254172 | bgmi